Keywords: eisai, b-ms, copromote, prohance, bristol-myers, squibb, reached
Eisai And B-MS To Copromote ProHance
Article | 17 July 1995
Eisai and Bristol-Myers Squibb have reached an agreement for the marketing of ProHance (gadoteridol), a magnetic resonance imaging contrast agent, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
